Summit completes initial dosing trials on Duchenne muscular dystrophy drug - Pharmaceutical Business Review: "Summit Therapeutics has completed the half-way stage of dosing of its Duchenne Muscular Dystrophy (DMD) candidate ezutromid in a 48-week phase 2 trial, dubbed PhaseOut DMD.
The UK-based Summit is likely to report results from the initial 24-week dosing period in the first quarter of 2018 which are anticipated to contain data from muscle biopsies, MRI and functional tests, and also safety data.
Summit Therapeutics chief operating officer and medical officer David Roblin said: "In the interim data readout, we aim to show a positive change following ezutromid treatment in muscle structure and health through the evaluation of muscle biopsies.
“This could potentially provide the first evidence of proof of mechanism for utrophin modulators in patients and give hope to those living with DMD.”"
'via Blog this'
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment